Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
The efficiency of artificial intelligence for management and clinical decision-making in the identification of patients with hidden HCV infection (Intelligen-C strategy)
1
Zitationen
8
Autoren
2025
Jahr
Abstract
INTRODUCTION: Artificial intelligence (AI) allows the optimization of diagnostic processes for hepatitis C virus (HCV) patients. Our objective was to evaluate the clinical, economic, and management benefits of an AI-based clinical decision support system (Intelligen-C strategy). METHODS: The Intelligen-C strategy consisted of (1) a retrospective phase (Dec 2013-Sep 2021), in which medical records were reviewed to search for anti-HCV-positive and/or HCV-RNA+ patients lost in the system, and (2) a prospective phase (Feb 2022-Jan 2023), in which automated screening (40-70 years) and routine testing for risk factors were performed in patients who were admitted to the emergency department or were hospitalized. With the use of automated screening, the system identified patients without an HCV diagnosis among those requiring blood tests and requested HCV serology; if the results were positive, reflex testing for HCV-RNA was performed. If a patient was HCV-RNA+, an alert was generated and sent to the hepatology department. In addition, the prospective phase was compared with the previous period to evaluate its effectiveness and efficiency. RESULTS: In the retrospective phase, the Intelligen-C strategy allowed the identification of 272 anti-HCV- or HCV-RNA+ patients who were lost to follow-up, of whom 11 were treated; in the prospective phase, after 7312 serologies were performed, 28 HCV-RNA+ patients were identified, 14 attended the appointment, and 9 were treated. In the prospective phase vs. the previous period, increased serology (7312 vs. 909), HCV-RNA+ detection (28 vs. 3), and treated patients (9 vs. 1) generated savings to the health system related to medical visits. In addition, Intelligen-C was cost-effective. CONCLUSIONS: The implementation of the Intelligen-C strategy allowed the identification of patients with undiagnosed infection, facilitated their diagnosis, reduced healthcare processes and associated hospital costs, and proved to be efficient.
Ähnliche Arbeiten
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
2002 · 6.393 Zit.
Hepatocellular carcinoma
2021 · 6.323 Zit.
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
2001 · 6.048 Zit.
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
2017 · 5.391 Zit.
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
2014 · 4.864 Zit.